Abbott Laboratories
corporate_fare Company Profile
Abbott Laboratories (NYSE:ABT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for ABT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ABT spans 10-Q, 8-K.
Recent high-impact activity:
- Abbott 10-Q: Q3 GAAP EPS $0.53 as Exact Sciences Amortization and $1.05B Legal Charges Hit Earnings
- Abbott Cuts 2026 Sales Growth Outlook to ~6% as Nutrition Spinoff Looms
- Abbott Q3 Sales Up 14.5%, Adjusted EPS $1.42; FY26 EPS Guidance Tightened to $5.50-$5.55
- Abbott to Spin Off Global Nutrition Unit via Tax-Free Distribution by End of 2027
- Abbott Posts 53-Cent Q3 EPS as Traders Await Full Results
Financial Snapshot
Short Interest & Short Volume
1.91 days to coverFINRA reported short interest of 19,058,208 shares in ABT as of the October 30, 2026 settlement, a 9.6% increase from the prior period — about 1.9 days to cover at its recent average daily volume. On November 19, 2026, 33.8% of ABT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.